Clinical Trial

A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

Study acronym: ELEVATUM
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is designed to investigate treatment response in treatment-naïve underrepresented patients with diabetic macular edema (DME) who are treated with faricimab. The study population will consist of participants ≥18 years of age who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander; in addition, a cohort of Asian Indian participants will be enrolled in India.
Trial Details
NCT Number NCT05224102
Lead Sponsor Genentech, Inc.
Conditions Diabetic Macular Edema
Enrollment 218 participants
Start Date 2022-02-28
Primary Completion 2027-01-26 (estimated)
Study Completion 2027-01-26 (estimated)
Updated on ClinicalTrials.gov 2026-05-27